Drugs and FDA

FDA approves neladalkib for previously treated ALK-positive lung cancer

The FDA approved neladalkib for adults with advanced ALK-positive lung cancer after alectinib or at least two prior ALK inhibitors plus platinum-based chemotherapy.

Reported by 3 outlets Wednesday, November 18, 2026

Cancer cells under a fluorescence microscope
Photo: CC0

The FDA granted accelerated approval on November 17, 2026, to neladalkib (Nelkarmi) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer previously treated with alectinib, or with at least two prior ALK inhibitors and platinum-based chemotherapy.

Approval was based on the ALKOVE-1 trial. Among 67 patients previously treated with alectinib, 49% responded, and 76% of responders had a response lasting at least 6 months. Among 155 patients treated with two or more prior ALK inhibitors and platinum-based chemotherapy, 32% responded, and 69% of responders had a response lasting at least 6 months. The FDA lists warnings for liver, kidney and eye toxicity, among other risks. An ongoing phase III trial is testing neladalkib as an initial treatment.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.